Dysferlin deficiency compromises the repair of injured muscle, but the underlying cellular mechanism remains elusive. To study this phenomenon, we have developed mouse and human myoblast models for dysferlinopathy. These dysferlinopathic myoblasts undergo normal differentiation but have a deficit in their ability to repair focal injury to their cell membrane. Imaging cells undergoing repair showed that dysferlin-deficit decreased the number of lysosomes present at the cell membrane, resulting in a delay and reduction in injury-triggered lysosomal exocytosis. We find repair of injured cells does not involve formation of intracellular membrane patch through lysosome–lysosome fusion; instead, individual lysosomes fuse with the injured cell membrane, releasing acid sphingomyelinase (ASM). ASM secretion was reduced in injured dysferlinopathic cells, and acute treatment with sphingomyelinase restored the repair ability of dysferlinopathic myoblasts and myofibers. Our results provide the mechanism for dysferlin-mediated repair of skeletal muscle sarcolemma and identify ASM as a potential therapy for dysferlinopathy.

Cell Death and Disease (2014) 5, e1306; doi:10.1038/cddis.2014.272; published online 26 June 2014

Dysferlinopathy is a progressive muscle wasting disease, which is classified as limb-girdle muscular dystrophy type 2B (LGMD2B) or Miyoshi muscular dystrophy 1, based on its muscle involvement.1,2 Dysferlin deficit leads to altered vesicle formation and trafficking,3,4 poor repair of injured cell membranes,5,6 and increased muscle inflammation.7,8 Dysferlin contains C2 domains that are found in Ca2+-dependent membrane fusion proteins such as synaptotagmins.9 Thus, dysferlin is thought to regulate muscle function by regulating vesicle trafficking and fusion.10–13 Dysferlin deficiency has also been implicated in conflicting reports regarding the fusion ability of dysferlinopathic myoblasts.4,14–16 With such diverse roles for dysferlin, the mechanism through which dysferlin deficiency results in muscle pathology is unresolved. As skeletal muscle-specific re-expression of dysferlin rescues all dysferlinopathic pathologies,17,18 myoblast repair has been suggested to be the unifying deficit underlying muscle pathology in dysferlinopathy.19 Repair of injured cell membranes requires subcellular compartments, which in mammalian cells include lysosomes,11 enlargeosomes,20 caveolae,21 dysferlin-containing vesicles,5 and mitochondria.22

Cells from muscular dystrophy patients that have normal dysferlin expression exhibit normal lysosome and enlargeosome exocytosis.23 However, dysferlinopathic muscle cells exhibit enlarged LAMP2-positive lysosomes, reduced fusion of early endosomes, altered expression of proteins regulating late endosome/lysosome fusion, and reduced injury-triggered cell-surface levels of LAMP1.4,11,12 In non-muscle cells, lack of dysferlin reduces lysosomal exocytosis.24 These findings implicate lysosomes in dysferlin-mediated muscle cell membrane repair. In one model for lysosome-mediated cell membrane repair, Ca2+ triggers vesicle–vesicle fusion near the site of injury, forming ‘membrane patch’, which fuses to repair the wounded cell membrane.25–28 In another model, lysosome exocytosis following cell membrane injury by pore-forming toxins leads to secretion of the lysosomal enzyme acid sphingomyelinase (ASM), which causes endocytosis of pores in the damaged cell membranes.21,29,30 Both these models have been suggested to be involved in the repair of injured muscle cells.21,28

To examine the muscle cell pathology in dysferlinopathy, we have developed dysferlinopathic mouse and human models. Use of these models shows that a lack of dysferlin does not alter myogenic differentiation but causes poor repair of even undifferentiated muscle cells. We show that dysferlin is required for tethering lysosomes to the cell membrane. Fewer lysosomes at the cell membrane in dysferlinopathic cells results in slow and reduced lysosome exocytosis following injury. This reduction in exocytosis reduces injury-triggered ASM secretion, which is responsible for the poor repair of dysferlinopathic muscle cells. Extracellular sphingomyelinase (SM) fully rescues the repair defect in dysferlinopathic cells and mouse myofibers, offering a potential drug-based therapy for dysferlinopathy.

Results

Dysferlin-deficient myoblasts undergo normal growth and differentiation. To characterize the role of dysferlin in myogenic cell growth and differentiation, we used two cellular...
models: (1) the C2C12 cell line, derived from a pool of cells with shDNA-mediated knockdown of dysferlin (C2C12-shRNA), and corresponding vector control cells (C2C12), and (2) a primary mouse myoblast clone isolated from immortalized carrying the A/J allele of dysferlin (dysf-KO) or the corresponding immortalize carrying normal dysferlin allele (dysf-wild type WT). Western blot analysis showed no detectable dysferlin expression in C2C12-shRNA or primary dysferlinopathic mouse myoblasts (Figures 1a and e). Following differentiation, dysferlin expression increased in the control cells, whereas dysferlinopathic cells still showed no detectable dysferlin expression (Figures 1a, b, e and f). Immunostaining of myotubes showed that as in control cells, the dysferlinopathic cells were able to form myotubes, but they lacked any detectable dysferlin expression (Figures 1c and g). Additionally, genotyping confirmed dysferlin mutation in dysf-KO myoblasts (Figure 1h).

To assess growth, we compared the doubling time for control and dysferlinopathic cells and found the times to be comparable: 17 h for C2C12 versus 16 h for C2C12-shRNA cells (Figure 1d). We also found comparable doubling times for mouse myoblasts: 17 h for WT-dysf versus 21 h for dysf-KO (Supplementary Figure 1A). In view of the proposed involvement of dysferlin in myogenesis through the regulation of myoblast fusion, we assessed the differentiation of these cells by monitoring the expression of myogenic markers, including desmin, myogenin, α-actin, and myosin heavy chain 3. Expression of all these myogenic markers increased similarly and steadily during the myogenic differentiation of control and dysferlinopathic cells and resulted in myotubes that were indistinguishable from each other (Figures 1b, c, f and g).

Dysferlin deficiency compromises myoblast cell membrane repair. Studies of laser-induced injury have established a role for dysferlin in sarcolemmal repair of myofibers and myotubes. To determine whether dysferlin also regulates myoblast cell membrane repair, we used two different cell injury approaches. In the first approach, a population of cells was injured using glass beads; all the injured cells were triggered with calcium ionophore (Figures 3f and g). As compared with uninjured myoblasts, we detected more LAMP1 on the surface of injured myoblasts (Figure 3a). Dysferlinopathic myoblasts showed significantly reduced (35% for dysf-KO, 30% for C2C12-shRNA) cell-surface LAMP1 when compared with corresponding healthy controls (Figures 3b and c).

Dysferlinopathic muscle cells show reduced injury-triggered lysosomal exocytosis. In view of the dependence of cell membrane repair on lysosome exocytosis and dysferlin, we investigated lysosomal exocytosis in dysferlinopathic myoblasts. To quantify the glass bead injury-induced increase in the cell-surface level of the lysosomal protein LAMP1, we injured myoblasts in the presence of TRITC-dextran (causing red staining of injured cells) and then probed for cell-surface LAMP1 in live cells using an antibody specific for the luminal domain of LAMP1. Using this approach, we have previously demonstrated that, independent of repair ability, cells that exocytose lysosomes show increased cell-surface LAMP1, whereas cells that fail to exocytose lysosomes do not. As compared with uninjured myoblasts, we detected more LAMP1 on the surface of injured myoblasts (Figure 3a). Dysferlinopathic myoblasts showed significantly reduced (35% for dysf-KO, 30% for C2C12-shRNA) cell-surface LAMP1 when compared with corresponding healthy controls (Figures 3b and c).

To establish whether the reduction in cell-surface LAMP1 was due to a reduction in injury-triggered lysosomal exocytosis, we monitored exocytosis of individual lysosomes following laser injury. Lysosomes were labeled with the luminal marker FITC-dextran and imaged using TIRF. As in our previous findings with calcium agonists, we observed injury-triggered exocytosis of individual lysosomes, as demonstrated by secretion of FITC-dextran by individual lysosomes (Figure 3d and Supplementary Video 3,4). Dysferlinopathic myoblasts undergoing repair showed a decreased number of injury-triggered exocytic events (>2-fold for dysf-KO, Figures 3d and e and Supplementary Figure 1C; 20% for C2C12-shRNA, Supplementary Figure 1B). A similar deficit was also observed when these cells were triggered with calcium ionophore (Figures 3f and g). These results demonstrate that reduced injury-triggered lysosomal exocytosis in dysferlinopathic cells is the result of a defect in Ca\(^{2+}\)-triggered lysosomal exocytosis.

In view of the patch model for cell membrane repair, we expected lysosomes to undergo Ca\(^{2+}\)-triggered homotypic fusion to form a ‘membrane patch’, followed by one large FITC-dextran flash caused by exocytosis of the patch vesicle. However, instead of homotypic calcium-triggered lysosome fusions we observed exocytosis of individual lysosomes to the injured cell membrane (Figures 3d–g). A variant of the patch model would involve compound exocytosis of lysosomes at the site of focal injury. We therefore examined the localization of exocytic events with respect to the site of injury. Each cell was divided into two equal halves along the long axis of the cell drawn from the site of injury, and exocytic events were quantified in the two halves (near and away from the site of injury). Exocytic events were uniformly distributed throughout the cell in WT and dysferlinopathic cells (Figures 3h and i), indicating that lysosome-mediated repair of the muscle cell membrane does not proceed by membrane patch formation.
Dysferlin is required for tethering lysosomes to the cell membrane. It was primarily the lysosomes present at the cell membrane whose exocytosis was triggered by cell injury (Supplementary Video 4). Preferential involvement of cell membrane-proximal lysosomes suggested a need for rapid lysosomal exocytosis for efficient membrane repair. We therefore examined the kinetics of injury-triggered lysosomal exocytosis in healthy and dysferlinopathic cells. Lysosomal exocytosis was triggered within seconds of injury and continued over the next couple of minutes as the cells underwent repair (Figures 4a and b). More than half of all exocytic events occurred within the first 15 s of injury, and it was the exocytosis of this pool of lysosomes that was reduced (3-fold) in dysferlinopathic cells (Figures 4a and b). There was no difference in the subsequent exocytic events between WT and dysferlinopathic cells, indicating that, unlike the dysferlin homologs the synaptotagmins, the lack of which prevents vesicle exocytosis, a lack of dysferlin delays but does not totally prevent calcium-triggered lysosomal exocytosis. This role of dysferlin in delaying (rather than blocking) lysosomal exocytosis may explain why the health of dysferlinopathic cells is poor, but they are not incapable of repair (Figures 2b and d and Supplementary Figure 2B).

In view of the recently identified role of dysferlin in stabilizing Ca\(^{2+}\) signaling in response to osmotic stress-induced myofiber injury, we asked whether altered lysosome exocytosis in dysferlinopathic cells is the result of a change in the kinetics of the injury-triggered Ca\(^{2+}\) increase in these cells. Using Fluo-4, we measured injury-triggered cytosolic Ca\(^{2+}\) dynamics and found no difference in the initiation and amplitude of the injury-triggered cytosolic Ca\(^{2+}\) increase between the control and dysferlinopathic cells (Figures 4c, d and f and Supplementary Figure 2C). However, in agreement with the slower repair of dysferlinopathic cells, an injury-triggered increase in cytosolic Ca\(^{2+}\) took longer to return to pre-injury values (Figures 4e and f and Supplementary Figure 2C).

Thus, in dysferlinopathic cells, reduced lysosomal exocytosis occurs in the first 15 s of injury despite the similar kinetics and amplitude of injury-triggered cytosolic Ca\(^{2+}\) increase in these cells. Using Fluo-4, we measured injury-triggered cytosolic Ca\(^{2+}\) dynamics and found no difference in the initiation and amplitude of the injury-triggered cytosolic Ca\(^{2+}\) increase between the control and dysferlinopathic cells (Figures 4c, d and f and Supplementary Figure 2C). However, in agreement with the slower repair of dysferlinopathic cells, an injury-triggered increase in cytosolic Ca\(^{2+}\) took longer to return to pre-injury values (Figures 4e and f and Supplementary Figure 2C).

In view of the recently identified role of dysferlin in stabilizing Ca\(^{2+}\) signaling in response to osmotic stress-induced myofiber injury, we asked whether altered lysosome exocytosis in dysferlinopathic cells is the result of a change in the kinetics of the injury-triggered Ca\(^{2+}\) increase in these cells. Using Fluo-4, we measured injury-triggered cytosolic Ca\(^{2+}\) dynamics and found no difference in the initiation and amplitude of the injury-triggered cytosolic Ca\(^{2+}\) increase between the control and dysferlinopathic cells (Figures 4c, d and f and Supplementary Figure 2C). However, in agreement with the slower repair of dysferlinopathic cells, an injury-triggered increase in cytosolic Ca\(^{2+}\) took longer to return to pre-injury values (Figures 4e and f and Supplementary Figure 2C).
This result demonstrates that re-expression of dysferlin restores the ability of the exocytic lysosomes to be tethered to the cell membrane and correlates well with previous reports of improved sarcolemmal repair as a result of dysferlin re-expression. To determine whether dysferlin regulates lysosome tethering by being localized to lysosomes, we examined whether dysferlin localizes to LAMP1-labeled lysosomes. We found that dysferlin (and dysferlin-GFP) localized to the cell membrane, endoplasmic reticulum, and some vesicular structures but did not co-localize with lysosomes (Figures 4j and k).

ASM is a potential drug therapy for dysferlinopathy. With no evidence to support the membrane patch model (Figures 3h and i), we next examined the model describing lysosome-mediated repair of cell membranes injured by pore-forming toxins. According to this model, injury-triggered secretion of lysosomal ASM facilitates repair. In view of the lysosomal exocytosis defects in dysferlinopathic cells, this model predicts a reduced/delayed secretion of ASM by these cells and further predicts that the deficit in ASM secretion would cause poor sarcolemmal repair. To test these hypotheses, we first examined the ASM expression in healthy and dysferlinopathic C2C12 cells and found their levels to be similar (Figure 5a, upper panel). Next, we asked whether, as in injury mediated by pore-forming toxins, mechanical injury would also trigger ASM secretion. Western blot analysis of culture supernatants of mechanically scrape-injured C2C12 and C2C12-shRNA cells allowed to repair for 5 min showed injury-triggered ASM secretion by both types of cell. Despite their equal cellular ASM levels (Figure 5a total ASM, lower panel), dysferlinopathic cells secreted less ASM than the corresponding control cells (Figure 5a secreted ASM, lower panel). To assess mechanical injury-triggered ASM secretion, we compared ASM activity in culture supernatants of C2C12 and C2C12-shRNA myoblasts following repair from scrape injury. Secreted ASM activity was reduced by 70% in dysferlinopathic C2C12-shRNA myoblasts, when compared with the healthy C2C12 cells (Figure 5b).

The observations reported above suggested that reduced ASM secretion as a result of defective lysosome docking and exocytosis correlates with poor repair of dysferlinopathic myoblasts. Therefore, we hypothesized that providing extracellular SM to injured dysferlinopathic cells could rescue their repair deficit. To test this hypothesis, we incubated dysferlinopathic myoblasts with 2 U/ml of SM and then injured them in the presence of FM dye. The presence of extracellular SM fully restored repair of C2C12-shRNA myoblasts after focal laser injury (Figure 5c, Supplementary Figure 3A, Supplementary Video 5).

To examine whether extracellular SM could serve as a potential therapy for dysferlinopathic patients, we used immortalized myoblasts derived from a LGMD2B patient. These cells lacked detectable dysferlin expression (Supplementary Figures 3B and C). As in the other
dysferlinopathic mouse myoblast models described here, myoblasts from this LGMD2B patient also formed normal myotubes (Supplementary Figure 3B). We then tested the cell membrane-repair capacity of these myoblasts and found that the patient's myoblasts did indeed have a compromised ability to repair their cell membranes (Figures 5d and e and Supplementary Videos 6 and 7). This cell membrane repair deficit in patient-derived myoblasts was fully reversed by treating the cells with extracellular SM (Figure 5f, Supplementary Figure S3D and Supplementary Videos 7 and 8).

To further evaluate the utility of extracellular SM treatment for improving dysferlinopathic muscle repair, we next tested the efficacy of SM treatment in rescuing the repair deficit of dysferlinopathic myofibers. For this purpose, we used extensor digitorum longus (EDL) and biceps muscles isolated from a dysferlin-deficient B6.A/J mouse.18 As compared with the EDL myofibers from parental WT (C57BL/6) mice, EDL myofibers from B6.A/J mice exhibited a significantly reduced repair ability (Figures 6a and b). EDL and biceps muscles injured following acute addition of 0.5 U/ml SM (without any pre-treatment) fully rescued the repair deficit seen in the dysferlinopathic myofibers (Figures 6a–c, Supplementary Videos 9 and 10).

It has been shown that extended exposure to SM leads to mitochondrial ROS production and reduced muscle contractile force.42 However, recombinant ASM delivered in vivo (in mice) is rapidly cleared from circulation, 40% within 1 min of delivery.43 Therefore, we examined the effect of brief SM treatment on the contractile force, fatigue, and force–frequency relationships in muscle from B6.A/J mice. We observed that the same SM treatment, which improved the repair ability of the myofibers (5 min treatment with 0.5 U/ml SM; Figures 6a–c), had no detectable effect on the specific force (Figure 6d), force–frequency relation (Figure 6e), or fatigability (Figure 6f) of the EDL muscle from B6.A/J mice.

Discussion

Despite over a century of research in the field of muscle injury and repair, there is still little understanding of the cellular mechanism involved in repairing injured myofibers. A decade ago, the discovery of dysferlin's role in the repair of injured myofibers offered the first suggestion that fusion of cellular vesicles is involved in the repair of injured muscle fibers.5 However, the identity of the vesicle responsible for mediating

Figure 3  Dysferlin deficiency reduces injury-triggered lysosomal exocytosis. (a) dysf-WT and dysf-KO myoblasts wounded in the presence of Ca\(^{2+}\) by glass beads in medium containing TRITC-dextran were stained for cell-surface LAMP1 (left panel); White arrows indicate the injured cells labeled (red) by TRITC dextran. Scale bar: 50 \(\mu\)m. (b and c) Reduced cell-surface LAMP1 staining in dysferlinopathic myoblasts following injury in the presence of Ca\(^{2+}\): cell-surface LAMP1 staining was quantified for \(>400\) dysf-WT, dysf-KO, C2C12, and C2C12-shRNA myoblasts each. (d and f) TIRF images showing dysf-WT myoblasts with FITC-dextran-labeled lysosomes. 'X' marks the sites of lysosome fusion following (d) laser injury or (f) ionomycin treatment. The orange line denotes the cell boundary. The inset in d shows a zoomed view of one lysosome as it underwent fusion, releasing FITC-dextran. Scale bar: 10 \(\mu\)m. (e and g) Quantification of lysosome fusions in \(>13\) dysf-WT and dysf-KO myoblasts, showing a reduced number of fusion events in dysferlinopathic myoblasts following (e) laser injury (168 lysosome fusions for dys-WT and 88 for dys-KO) and (g) ionophore treatment (264 fusions for dys-WT and 112 for dys-KO). (h and i) Localization of lysosome exocytosis sites (168 for dys-WT, 88 for dys-KO, 350 for C2C12, and 385 for C2C12-shRNA) with respect to the site of injury in (h) C2C12 or (i) primary myoblasts (n\(\geq10\) cells each). Data are mean ± S.E.M. * \(P<0.05\) and *** \(P<0.001\) by unpaired Student’s t-test.
the repair of injured myofibers and the role that dysferlin has in this process have remained elusive. Understanding how injured myofibers undergo repair is not only crucial because muscle injury is widespread but also because the lack of this knowledge has hampered the development of therapies for muscular dystrophies, including LGMD2B, Miyoshi myopathy, LDM2L, and dystroglycanopathies, all of which are associated with poor sarcolemmal membrane repair. 5,23,44

Some of the effects of dysferlin deficiency on muscle tissue have been attributed to poor differentiation of the dysferlinopathic myoblasts. 4,32 The various mouse and human myoblast cell lines we have described here, although useful for studying the cell biological aspects of dysferlin deficiency in muscle cells in vitro, do not support a role for dysferlin deficiency in myoblast differentiation in culture. Thus, these cells are not suitable for testing any potential effect of dysferlin on muscle cell differentiation. However, our finding, across all these mouse and human cellular models, that dysferlin deficiency causes poor repair of dysferlinopathic myoblasts makes these cells an excellent model for screening drugs to improve the repair of dysferlinopathic muscle cell membranes. We also show that a lack of dysferlin results in delayed and reduced lysosome exocytosis as a result of poor tethering of lysosomes to the cell membrane (Figures 3 and 4). This reduced exocytosis may explain the subsarcolemmal vesicle accumulation reported in dysferlin-deficient muscles, 45 and it...
is in agreement with the increased accumulation of lysosomes reported in dysferlinopathic muscle cells.\(^4\)

Despite the requirement of dysferlin for cell membrane localization of lysosomes, we find that dysferlin itself is not localized to lysosomes. This supports previous reports that dysferlin is localized to the sarcolemma and T-tubules,\(^{46,47}\) but not to lysosomes.\(^{28}\) This also makes dysferlin similar to the cell membrane-localized synaptotagmin isoform, which regulate calcium-triggered vesicle tethering/fusion of the vesicle to the cell membrane by interacting with vesicular SNARES or synaptotagmins.\(^{47}\) Some of the dysferlin-interacting molecules have been identified and include injury-sensing\(^{48}\) and fusion-regulating proteins such as annexins.\(^{11}\) However, further work is needed to identify the SNAREs and lysosomal proteins that interact with dysferlin and facilitate lysosome docking and fusion to the injured cell membrane.

Through live imaging of lysosomes, we have shown here that lysosome-mediated sarcolemmal repair does not involve the proposed membrane patch model of cell membrane repair. Instead, lysosomes tethered to the cell membrane exocytose individually in response to injury, resulting in injury-triggered secretion of ASM. This process is compromised in the dysferlinopathic cells and is the basis for the poor repair of dysferlinopathic muscle. By demonstrating reduced lysosomal exocytosis and reduced ASM secretion by dysferlinopathic muscle cells, our study offers direct evidence in support of a role for ASM secretion in the repair of mechanical injury to dysferlinopathic muscle cells and myofibers. The mechanism of this repair may involve endocytosis\(^{21,29}\) and bleb formation,\(^{30,41}\) which are proposed on the basis of pore-forming toxin-induced injury. However, it is worth noting that the repair of dysferlinopathic sarcolemma after pore-forming toxin-mediated injury is distinct from the repair after mechanical injury, as dysferlin-deficient muscle recovers normally from sarcolemmal damage caused by the cell membrane pore-forming plant metabolite saponin.\(^{49}\) Other effects of ASM could be mediated by its ability to hydrolyze cell membrane sphingomyelin. This hydrolysis would result in the formation of membrane microdomains, which can regulate signaling, fluidity, and cytoskeleton organization at the cell membrane.\(^{50,51}\) These processes that regulate membrane properties and cell membrane repair.\(^{52,53}\) In agreement with a role for membrane properties in the repair of injured membranes, we recently observed that the use of a membrane-active steroid analog improves the repair of injured cell membranes.\(^{54}\) Thus, additional work is needed to elucidate the complete sequence of steps by which reduced ASM secretion following mechanical injury results in poor repair of dysferlinopathic muscle.

Beyond regulating sarcolemmal properties and sarcolemmal repair, ASM can also aid in the repair of injured

---

**Figure 5** Reduced ASM secretion by dysferlinopathic cells and rescue of their repair ability by sphingomyelinase (SM) treatment. (a) Western blot for cellular ASM expression in three independent C2C12 cultures (upper panel). Lower panel shows the same for a representative experiment in which the scrape injury-triggered secretion of ASM was compared in C2C12 and C2C12-shRNA cells. (b) Activity levels of secreted ASM after scrape injury of C2C12 and C2C12-shRNA myoblast cultures (n = 4). (c) Quantification of FM1-43 influx following laser injury of C2C12 myoblasts and SM-treated and untreated C2C12-shRNA myoblasts (n = 17 cells each). Note the rescue of the repair deficit in C2C12-shRNA cells by SM treatment. (d) Time-lapse images and (e) quantification (n > 16 cells each) showing FM1-43 influx in control or LGMD2B patient myoblasts following focal laser injury, with poor repair of patient myoblasts. Scale bar: 100 μm. White box marks the injured region. (f) Quantification of FM1-43 influx following laser injury in control and SM-treated (2 U/ml) or untreated LGMD2B patient myoblasts (n > 19 myoblasts each), showing full rescue of the repair defect in patient myoblasts. Data are means ± S.E.M. \(*P < 0.05, **P < 0.01, and ***P < 0.001\) (comparison of mutant and corresponding WT samples); \(##P < 0.01\) and \(###P < 0.001\) (treated versus untreated dysferlinopathic samples) compared by unpaired Student's t-test.
muscle tissue through its other roles in reducing muscle contractile force and the calcium sensitivity of the muscle contractile apparatus.42 This role of ASM could protect the injured muscle by reducing the potential for contraction-induced re-injury. Also, the ASM-ceramide system can regulate inflammation by regulating the release of pro-inflammatory cytokines.55 Finally, by increasing basal and insulin-induced glucose uptake in skeletal muscles, 56 ASM can increase inflammation by regulating the release of pro-inflammatory cytokines.55 ASM can increase metabolism and aid the recovery of injured muscle cells. Dysferlin deficiency could affect one or more of the above-mentioned benefits of injury-triggered ASM secretion. Thus, in addition to the myofiber repair deficit, reduction in these effects could further contribute to poor repair of dysferlinopathic muscles. Thus, our results not only identify the cellular mechanism underlying the poor repair of dysferlinopathic muscle but also point to novel aspects of dysferlin deficit on muscle repair.

Our finding that acute SM treatment is sufficient to improve the repair ability of the dysferlinopathic myofibers demonstrates its potential as a therapy for dysferlinopathy. Deleterious effect of long-term SM treatment on muscle function is a source of some concern.42 However, our findings demonstrate its potential as a therapy for dysferlinopathy.

ASM treatment is as a therapeutic option that could be evaluated for its clinical efficacy for dysferlinopathic patients.

Materials and Methods

Cell culture. The stable C2C12-shRNA mouse clone was derived from a C2C12 dysferlin shRNA pool, as described elsewhere.31 Immortalized mouse primary cells, dysf-WT and dysf-KO, were a gift from Dr Terry Partridge and were derived from dysferlinopathic (B6.A/J) mice. Treatment of dysferlinopathic myofibers with SM (0.5 U/ml) fully rescued the sarcolemmal repair deficit. Scale bar: 50 μm. White box marks the region injured by the laser. (c) Quantification of FM1-43 influx following laser injury into SM-treated and untreated biceps myofibers (n > 14) isolated from dysferlinopathic (B6.A/J) mice. Specific force of SM-treated and untreated dysferlinopathic EDL (n = 5) muscle from B6.A/J. (f) Fatigue characteristics (n > 5) of SM-treated or untreated dysferlinopathic EDL muscle from B6.A/J mice. Data are means ± S.E.M. *P < 0.05 and **P < 0.01 (comparison of mutant and corresponding WT samples); #P < 0.001 (treated versus untreated dysferlinopathic samples); all compared by unpaired Student’s t-test.

Cell culture. Cells were isolated from the pectoralis major muscle of a 41-year-old male. For cell doubling-time calculations, cells cultured thrice in triplicate were harvested and counted on each day of culture, and these cell numbers were used to determine the culture’s doubling time.

SM treatment of cells. Cells cultured on coverslips were pre-incubated for 20 min with 2 U/ml of Bacillus SM (Sigma-Aldrich, St. Louis, MO, USA) in growth medium and then laser-injured in cell imaging medium (CIM: HBSS with 10 mM HEPES, pH 7.4) containing 1 μg/μl FM1-43 dye and 2 U/ml of SM as described below.

Transfection of dysf-GFP plasmid. C2C12 or C2C12-shRNA myoblasts were transfected with dysf-GFP using Lipofectamine LTX (Life Technologies, Carlsbad, CA, USA) for 24-48 h.

Western blotting and immunostaining. Cells were lysed with RIPA buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Fisher Scientific, Waltham, MA, USA) or fixed with 4% paraformaldehyde (PFA), then permeabilized with 0.1% Triton X-100. Proteins transferred to nitrocellulose membranes were probed with the indicated antibodies against: ASM (Abcam, Cambridge, MA, USA), desmin (Santa Cruz, Dallas, TX, USA), dysferlin (Novoceastra, Buffalo Grove, IL, USA), myogenin (Dako, Carpinteria, CA, USA), GAPDH (Santa Cruz), myosin heavy chain 3 (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) and myosin heavy chain 2a (Merck, Darmstadt, Germany).

Figure 6 Sphingomyelinase (SM) treatment rescues the repair ability of dysferlinopathic myofibers without affecting their contractile force. (a) Time-lapse images and (b) quantification of FM1-43 influx, following laser injury, into SM (0.5 U/ml) -treated and untreated EDL myofibers (n = 15) isolated from healthy (C57BL/6) and dysferlinopathic (B6.A/J) mice. Treatment of dysferlinopathic myofibers with SM (0.5 U/ml) fully rescued the sarcolemmal repair defect. Scale bar: 50 μm. White box marks the region injured by the laser. (c) Quantification of FM1-43 influx following laser injury into SM-treated and untreated biceps myofibers (n > 14) isolated from dysferlinopathic (B6.A/J) mice. (d) Specific force of SM-treated and untreated dysferlinopathic EDL (n = 5) muscle from B6.A/J. (e) Frequency–force curve of SM-treated and untreated dysferlinopathic EDL (n = 5) muscle from B6.A/J. (f) Fatigue characteristics (n > 5) of SM-treated or untreated dysferlinopathic EDL muscle from B6.A/J mice. Data are means ± S.E.M. *P < 0.05 and **P < 0.01 (comparison of mutant and corresponding WT samples); #P < 0.001 (treated versus untreated dysferlinopathic samples); all compared by unpaired Student’s t-test.
Iowa City, IA, USA); and α-actinin (Epitomics, Burlingame, CA, USA). Primary antibodies were followed by the appropriate HRP-conjugated secondary antibodies (Sigma-Aldrich), and chemiluminescent western blotting substrate (Fisher, Waltham, MA, USA; GE Healthcare, Pittsburgh, PA, USA) then processed on Bio-Lite X-ray film (Denville Scientific, Metuchen, NJ, USA). For immunostaining, permeabilized cells were reacted with anti-dyferlin (Epitomics) and anti-LAMP1 (Santa Cruz) antibodies, followed by fluorophore-conjugated secondary antibodies: Alexa Fluor 488-anti-rabbit, Alexa Fluor 594-anti-rat, and Alexa Fluor 594-anti-mouse (Life Technologies). Nuclei were counterstained with Hoechst 33342. After mounting in mounting medium (Dako), cells were imaged as described in Supplementary Methods.

PCR genotyping. Total DNA was isolated from dysf-WT and dysf-KO immortalized mouse primary cells and used for genotyping. The primers used to identify the dyferlin mutation (AJU Etn insertion in intron 4) in dysf-WT and dysf-KO cells were: dys-F, 5'-TTCCTCCTTGCTGCTCAG-3'; dys-R, 5'-CTCAGTCGGAAATGTGCTG-3'; Etn-DR, 5'-GCCCCTGAGACAGATACGTGCTG-3', as described previously.6 To assess the status of the dysferlin allele, genomic DNA was PCR-amplified using Dysf (dys-F and dys-R) primers, resulting in the amplification of a 207-bp fragment for the dysferlin allele, not disrupted by the Etn transposon sample (dysf-WT). A lack of this band indicates Etn transposon insertion in the dysferlin allele (dysf-KO). Independently, to establish Etn insertion, genomic DNA was PCR-amplified using Ettn-DR and dysf-R primers, resulting in a 234-bp fragment for the allele that contains the Etn insertion and no amplification of the dysf-WT allele.

Injury assays. These assays were performed as described previously and listed below.35

Glass bead injury. Cells cultured on coverslips were transferred to CIM or PBS (Sigma-Aldrich) containing 2 mg/ml of lysine-fixable FITC-dextran (Life Technologies). Cells were injured by rolling glass beads (Sigma-Aldrich) over the cells. They were allowed to heal at 37 °C for 5 min, and then incubated at 37 °C for 5 min in CIM/PBS buffer containing 2 mg/ml of lysine-fixable TRITC-dextran (Life Technologies). Cells were fixed in 4% PFA, and nuclei were counterstained with Hoechst 33342; the cells were then mounted in fluorescence mounting medium (Dako) and imaged as described in Supplementary Methods. The number of FITC-positive cells (injured and repaired) and TRITC-positive cells (injured and not repaired) were counted. The number of injured cells that failed to be repaired was expressed as a percentage of the total injured cells.

Laser injury. Cells cultured on coverslips were transferred to and incubated in CIM/PBS buffer with 1 μg/ml FM 4-34 dye (Life Technologies) and placed in a Tokai Hit microscopy stage-top ZILCS incubator (Tokai Hit Co., Fujinomiya-shi, Shizuoka, Japan) at 37 °C. For laser injury, a 1- to 5-μm2 area was irradiated for <10 ms with a pulsed laser (AbiLase, 3i Intelligent Imaging Innovations, Inc. Denver, CO, USA). Cells were imaged at 2 s intervals using an IX81 Olympus microscope (Olympus America, Center Valley, PA, USA) as described in Supplementary Methods. FM dye intensity (ΔFF/Fo, where F is the original value) was used to quantify the kinetics of cell membrane repair and represented with intervals of five frames.

Monitoring injury triggered changes in cell-surface LAMP1 levels. Changes were monitored as described previously.35 Cells cultured on coverslips were injured as described above by rolling of glass beads in the presence of lysine-fixable TRITC-dextran. After allowing repair to occur for 5 min, at 37 °C and blocking with 3% BSA (in CIM) for 10 min at 4 °C, cell-surface LAMP1 was immunolabeled for 30 min at 4 °C using antibody specific for the luminal domain of LAMP1 (Santa Cruz) in blocking solution, followed by labeling with Alexa Fluor Fluor 488-anti-rabbit antibody (Life Technologies) for 15 min at 4 °C. Cells fixed in 4% PFA were stained with Hoechst 33342 and imaged as described in Supplementary Methods. The increase in cell-surface LAMP1 staining intensity of individual injured (TRITC-positive) cells was normalized to the average cell-surface LAMP1 staining intensity of all (>125) unjured (TRITC-negative) cells. The percentage increase in cell-surface LAMP1 staining for each injured cell was then determined (divided by the average value for the uninjured cells). This percentage increase was then averaged for all the injured cells (>400 measured).

Live imaging of cell membrane injury-triggered lysosomes. Cells were subjected to the live imaging of cell membrane injury-triggered lysosome assay as described.35 Cultured cells on coverslips were incubated overnight with growth medium containing 2 mg/ml of fluorescent-dextran. The cells were then washed and incubated for 2 h with growth medium; following laser injury, they were imaged with TIRF as described in Supplementary Methods. The number of lysosomes/μm² (exocytic or proximal) was counted for each cell, and the value presented is that for the average area occupied by C2C12 myoblasts (3000 μm²) or primary myoblasts (1200 μm²).

Imaging Ca²⁺ influx into cells after laser injury. C2C12 and C2C12-shRNA cells cultured on coverslips were incubated with DMEM without FBS that contained 10 μM Fluo-4-AM (Life Technologies) for 20 min at 37 °C and 5% CO₂. After washing with pre-warmed CIM, the cells were laser injured in CIM as described above and imaged at 4–6 frames/s. The kinetics of Ca²⁺ influx was measured as the ratio of cellular Fluo-4-AM emission (ΔF/Fo, where F is the Fluo-4 intensity before injury). Images show this intensity ratio, generated using Metamorph7.0 (Molecular Devices, Sunnyvale, CA, USA).

ASM enzyme assay. C2C12 or C2C12-shRNA was washed and incubated with Ca²⁺-free PBS for 10 min at 37 °C. Cells were then injured (or not) by scraping in pre-warmed CIM and incubated for 5 min to repair at 37 °C. After repair, the culture media was collected, and cell lysates prepared as described before. The Amplex Red sphingomyelinase assay kit (Life Technologies) was used to assess ASM activity in the culture supernatants and cell lysates. For each sample, the secreted ASM activity was normalized to the activity in the lysate. Activity following injury was expressed as a percentage increase compared with the no-injury sample.

Fibers isolation, membrane injury, and SM treatment. Methods involving animals were approved by the local institutional animal research committee, and animals were maintained in a facility accredited by the American Association for Accreditation of Laboratory Animal Care. EDL muscle was surgically isolated from euthanized 3-month-old C57BL/6 or B6.A/J mice in Tyröde’s solution containing 128 mM NaCl, 4.7 mM KCl, 1.36 mM CaCl₂, 2 mM NaHCO₃, 0.36 mM NaH₂PO₄, 1 mM MgCl₂, and 10 mM glucose (pH 7.4), and biopsed muscle was surgically isolated from euthanized 7-month-old B6.A/J mice in Tyröde’s solution. Laser injury was carried out as described above in the Tyröde’s buffer containing 1.33 μg/ml FM 4-34 dye. The kinetics of repair were determined by measuring the cellular FM 4-34 dye fluorescence. For SM treatment, freshly isolated muscle was laser injured as described above but in the presence of 0.5 μM/ml of Bacillus SM (Sigma-Aldrich), added before injury.

Skeletal muscle contractile properties measured in vitro. Mice (7-month-old B6.A/J and 3-month-old C57BL/6) were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). After the EDL muscle was exposed, 5-0 silk sutures were tied securely to the distal and proximal tendons. The muscle was then carefully removed from the mouse and placed vertically in a bath containing buffered mammalian Ringer’s solution (composition in mM: 137 NaCl, 24 NaHCO₃, 11 glucose, 5 KCl, 2 CaCl₂, 1 MgSO₄, 1 NaH₂PO₄, and 0.025 taurine carboxylate). The distal tendon was attached to a fixed bottom plate and the proximal tendon to the arm of a dual servomotor (Aurora Scientific, Aurora, ON, Canada, model 305B). The temperature of the Ringer’s solution was maintained at 25 °C and bubbled with 95% O₂–5% CO₂. The EDL muscle was stimulated between two stainless steel plate electrodes flaming the muscle. The voltage of single 0.2-ms² stimulation pulses was increased until supramaximal stimulation of the muscle was achieved. Subsequently, muscle length was adjusted to the length that resulted in maximal twitch force (i.e., optimal length for force generation). With the muscle held at optimal length, the force developed during trains of stimulation pulses (i.e., tetanic contraction) was recorded. The stimulation frequency was increased in intervals of 2-min steps of 30 and 20 Hz (30, 50, 80, 100, 120, 150, 180, 200, 220, and 250 Hz) till the maximal isometric tetanic force (plateau) was achieved. For the EDL muscle, 300-ms trains of pulses were used, separated by 2 min of rest. SM was then added to the Ringer’s solution (0.5 μM/ml), and the same muscle was stimulated with increases in steps of 30 and 20 Hz till the maximal isometric force was repeated. Finally, the fatigue response of the muscle, exposed to SM, was measured with 60 isometric contractions, once every 5s, and compared with that of B6.A/J mouse muscles fatigued in Ringer’s solution. The stimulation duration of each contraction was 400 ms. The muscle length was measured with calipers, and the optimal fiber length was calculated by multiplying the optimal muscle length by 0.45, an established fiber length/muscle length ratio for EDL muscle.39 The muscle...
mass was weighed after removal of the muscle from the bath. The muscle-specific force, a measure of intrinsic force generation of muscle, was calculated using the maximal isometric force, the muscle mass, and the fiber length according the following equation: specific force = maximal isometric force/muscle mass × (density of muscle tissue × fiber length)³. Muscle tissue density is 1.056 kg/l.

For the fatigue protocol, the force for the first concentration was set at 100%, and the force measured at 1, 2, 3, 4, and 5 min was compared with the first value and expressed as percentages.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was funded by grants from the NIH/NIAMS (AR55686, HD040677, AR060836) and MDA (MDA777389) to J.KJ, and from the AFM to AD. KN is supported by the NIH (K26OD011711; R24HD05846), the MDA (translational grant), and the US Department of Defense (W81XWH-05-1-0659, W81XWH-11-1-0782, W81XWH-11-1-0330). Drs Terry Partridge and Jonathan Cohen generated the pool of dys-WT and dys-KO immortomouse myoblasts from which the clone used here was identified. Dr Isabelle Richard provided the B6.A/J mice, and Dr Eduardo Gallardo provided the patient biopsy. AB generated the immortalized A/J mouse for the platform to immortalize for human cells at the institute de Myologie, Paris. RBG generated the C2C12-shRNA cells with funding from Jain Foundation. We thank Dr Deborah McClellan for editorial assistance. JKJ and AD designed the study, analyzed data, and wrote the paper. AD performed all experiments, with help from RBG with the glass bead-injury experiments. JHVdM performed the EDL force measurements, and KN assisted in data analysis and writing the paper.

1. Bashir R, Britton S, Strachan T, Keers S, Vafaiadaki E, Lako M et al. A gene related to Caenorhabditis elegans spermagenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998; 20: 37–42.

2. Liu J, Axol M, Ila A, Wu C, Fardeau M, Angelini C et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 2001; 28: 25–31.

3. Canacchi G, Fanin M, De Giorgi LB, Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005; 58: 190–195.

4. Demonbreun AR, Fahrenbach JP, Deveaux K, Earley JU, Pytel P, McNally EM. Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-deficient dystrophy. Hum Mol Genet 2011; 20: 779–789.

5. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 2001; 28: 25–31.

6. Ho M, Post CM, Donahue LR, Libov HG, Bronson RT, Gooch H et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dystrophin deficiency. Hum Mol Genet 2004; 13: 1993–2000.

7. Gallardo E, Rojas-Garcia R, de LN, Pou A, Brown Jr RH, Illa I. Inflammation in dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy type B. J Biol Chem 2013; 288: 2325–2336.

8. Bonnemann CG, McNally EM, Kurikel LM. Beyond dystrophin: current progress in the muscular dystrophies. Curr Opin Pediatr 1996; 8: 569–582.

9. Lee A, Eveson FJ, Sutton RB, North KN, Cooper ST. Fertilins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair. Membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003; 423: 168–172.

10. Bos APJ, Dembreun A, McNally EM. Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol 2011; 96: 203–230.

11. Lennon NJ, Kho A, Bacska SJ, Perfitt-Muller SL, Hyman BT, Brown JR. Dystrophin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Cell Sci 1996; 100: 569–582.

12. Kesen A, Fukuda M, Knoblauch B, Bashir R, Nader GA, Rao D et al. Dysferlin deficiency shows compensatory induction of Rab27A/Sp20 that may contribute to inflammatory onset. Am J Pathol 2008; 173: 1476–1487.

13. Nagaraju K, Rawat R, Veselovskyh E, Thapily RD, Kesen A, Sparks S et al. Dysferlin deficiency enhances monocye phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 2008; 172: 774–785.

14. de Luna N, Gallardo E, Soriano M, Dominguez-Perles R, de la Torre C, Rojas-Garcia R et al. Absence of dysferlin alters myosin expression and delays human muscle differentiation in vitro. J Biol Chem 2008; 283: 17092–17098.

15. Humphrey GW, Melkadow V, Blank PS, de MA, Pekkumaz G, Nagaraju K et al. OREG cells, a dysferlin-deficient myogenic cell line. Exp Cell Res 2012; 318: 127–135.

16. Philippo S, Bigot A, Marg A, Moul Y, Spuler S, Zacharias U. Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dystrophinopathy. PLoS Curr 2012; 4: RIN1298.
47. Sudhof TC. Synaptotagmins: why so many? J Biol Chem 2002; 277: 7629–7632.
48. Cai C, Msumuya H, Weisleder N, Matsuda N, Nishi M, Hwang M et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 2009; 11: 56–64.
49. Zhao P, Xu L, All-Mou Y, de Tombe PP, Han R. Equal force recovery in dysferlin-deficient and wild-type muscles following saponin exposure. J Biomed Biotechnol 2011; 2011: 235216.
50. van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J. Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J 2003; 369: 199–211.
51. Grassme H, Jendrossek V, Bock J, Riehle A, Gubins E. Ceramide-rich membrane rafts mediate CD40 clustering. J Immuno 2002; 168: 298–307.
52. McNeil PL, Steinhardt RA. Plasma membrane disruption: repair, prevention, adaptation. Annu Rev Cell Dev Biol 2003; 19: 697–731.
53. Jaiswal JK, Lauritzen SP, Scheffer L, Sakaguchi M, Bunkenborg J, Simon SM et al. S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells. Nat Commun 2014; 5: 3795.
54. Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 2013; 5: 1589–1585.
55. Grassme H, Becker KA, Zhang Y, Gubins E. Ceramide in bacterial infections and cystic fibrosis. Biol Chem 2008; 389: 1371–1379.
56. Turinsky J, Nagel GW, Elmendorf JS, Damrau-Abney A, Smith TR. Sphingomyelinase stimulates 2-deoxyglucose uptake by skeletal muscle. Biochem J 1996; 313(Pt 1): 215–222.
57. Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 2007; 30: 654–660.
58. Brooks SV, Faulkner JA. The magnitude of the initial injury induced by stretches of maximally activated muscle fibres of mice and rats increases in old age. J Physiol 1996; 497(Pt 2): 573–580.